The importance of variant reinterpretation in inherited cardiovascular diseases: Establishing the optimal timeframe.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 29 09 2023
accepted: 15 01 2024
medline: 1 5 2024
pubmed: 1 5 2024
entrez: 1 5 2024
Statut: epublish

Résumé

Inherited cardiovascular diseases are rare diseases that are difficult to diagnose by non-expert professionals. Genetic analyses play a key role in the diagnosis of these diseases, in which the identification of a pathogenic genetic variant is often a diagnostic criterion. Therefore, genetic variant classification and routine reinterpretation as data become available represent one of the main challenges associated with genetic analyses. Using the genetic variants identified in an inherited cardiovascular diseases unit during a 10-year period, the objectives of this study were: 1) to evaluate the impact of genetic variant reinterpretation, 2) to compare the reclassification rates between different cohorts of cardiac channelopathies and cardiomyopathies, and 3) to establish the most appropriate periodicity for genetic variant reinterpretation. All the evaluated cohorts (full cohort of inherited cardiovascular diseases, cardiomyopathies, cardiac channelopathies, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, Brugada syndrome, long QT syndrome and catecholaminergic polymorphic ventricular tachycardia) showed reclassification rates above 25%, showing even higher reclassification rates when there is definitive evidence of the association between the gene and the disease in the cardiac channelopathies. Evaluation of genetic variant reclassification rates based on the year of the initial classification showed that the most appropriate frequency for the reinterpretation would be 2 years, with the possibility of a more frequent reinterpretation if deemed convenient. To keep genetic variant classifications up to date, genetic counsellors play a critical role in the reinterpretation process, providing clinical evidence that genetic diagnostic laboratories often do not have at their disposal and communicating changes in classification and the potential implications of these reclassifications to patients and relatives.

Identifiants

pubmed: 38691546
doi: 10.1371/journal.pone.0297914
pii: PONE-D-23-30046
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0297914

Informations de copyright

Copyright: © 2024 Fernandez-Falgueras et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

Ramon Brugada is a consultant for Genincode. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Auteurs

Anna Fernandez-Falgueras (A)

Department of Cardiology, Hospital Trueta, Girona, Spain.
Molecular Diagnostics and Personalized Medicine Unit, Clinical Laboratory, Hospital Trueta, Girona, Spain.
Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Monica Coll (M)

Molecular Diagnostics and Personalized Medicine Unit, Clinical Laboratory, Hospital Trueta, Girona, Spain.
Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Anna Iglesias (A)

Molecular Diagnostics and Personalized Medicine Unit, Clinical Laboratory, Hospital Trueta, Girona, Spain.
Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Coloma Tiron (C)

Department of Cardiology, Hospital Trueta, Girona, Spain.
Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Medical Science Department, School of Medicine, University of Girona, Girona, Spain.

Oscar Campuzano (O)

Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Medical Science Department, School of Medicine, University of Girona, Girona, Spain.

Ramon Brugada (R)

Department of Cardiology, Hospital Trueta, Girona, Spain.
Molecular Diagnostics and Personalized Medicine Unit, Clinical Laboratory, Hospital Trueta, Girona, Spain.
Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Medical Science Department, School of Medicine, University of Girona, Girona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH